| Literature DB >> 32296102 |
Itty Sethi1, Varun Sharma1, Indu Sharma1, Gurvinder Singh2, Gh Rasool Bhat1, A J S Bhanwer2, Swarkar Sharma3, Ekta Rai4.
Abstract
Telomere length attrition has been implicated in various complex disorders including Type 2 Diabetes (T2D). However, very few candidate gene association studies have been carried out worldwide targeting telomere maintenance genes. In the present study, variants in various critical telomere maintenance pathway genes for T2D susceptibility in Northwest Indian population were explored. With case-control candidate gene association study design, twelve variants from seven telomere maintenance genes were evaluated. Amongst these five variants, rs9419958 (OBFC1), rs4783704 (TERF2), rs16847897 (TERC/LRRC31), rs10936599 (TERC/MYNN), and rs74019828 (CSNK2A2) showed significant association with T2D (at p-value ≤ 0.003, threshold set after Bonferroni correction) in the studied population. In silico analyses of these variants indicated interesting functional roles that warrant experimental validations. Findings showed that variants in telomere maintenance genes are associated with pathogenesis of T2D in Northwest Indian population. We anticipate further, such candidate gene association studies in other Indian populations and worldwide would contribute in understanding the missing heritability of T2D.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32296102 PMCID: PMC7160122 DOI: 10.1038/s41598-020-63510-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Distribution of epidemiological parameters between Type 2 Diabetes patients and Healthy Controls populations from North India.
| S.No. | Characteristic | Cases* | Controls | |
|---|---|---|---|---|
| 1. | Age | 58.1 ± 8.02 | 58.58 ± 10.87 | 0.35 |
| 2. | Gender - Male | 444 (65.1%) | 330 (49.1%) | — |
| Gender - Female | 238 (34.9%) | 342 (50.9%) | — | |
| 3. | BMI-kg/m2 | 26.4 ± 4.39 | 25.45 ± 4.01 | 9E-04 |
| 4. | Systolic Blood Pressure (SBP)-mmHg | 135.07 ± 17.15 | 127.88 ± 14.32 | 7.22E-11 |
| 5. | Diastolic Blood Pressure (DBP)-mmHg | 86.64 ± 10.45 | 82.68 ± 7.52 | 1.86E-10 |
| 6. | Blood Glucose (Post Prandial)-mg/dl | 216.56 ± 68.66 | 120.32 ± 20.83 | 1.2E-107 |
| 7. | Triglycerides | 256.98 ± 173.99 | 178.72 ± 109.2 | 4.84E-15 |
| 8. | High Density Lipoproteins (HDL) | 49.92 ± 28.04 | 48.12 ± 21.9 | 0.3 |
| 9. | Very Low Density Lipoprotein (VLDL) | 51.39 ± 34.79 | 35.98 ± 22.18 | 1.73E-14 |
| 10. | Cholesterol | 170.89 ± 50.44 | 163.68 ± 47.92 | 0.04 |
*Other clinical conditions removed.
Allelic Distribution. Logistic regression analysis of significant variants of genes in our study, adjusted for age, gender and BMI.
| VARIANT | rs9419958 | rs4783704 | rs16847897 | rs10936599 | rs74019828 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| NEAREST GENE (VARIANT) | ||||||||||
| POLYMORPHISM (ref/alt-GRCh38/hg38) | ||||||||||
| ANCESTRAL ALLELE | ||||||||||
| ALLELE DISTRIBUTION | ||||||||||
| CASES (n = 682) | 0.04 | 0.96 | 0.13 | 0.87 | 0.43 | 0.57 | 0.16 | 0.84 | 0.07 | 0.93 |
| CONTROLS (n = 672) | 0.07 | 0.93 | 0.16 | 0.84 | 0.38 | 0.62 | 0.27 | 0.73 | 0.15 | 0.85 |
| ALLELIC ODDS RATIO (95% CI) | 1.98 (1.38–2.85) | 1.32 (1.06–1.65) | 1.23 (1.05–1.44) | 1.76 (1.46–2.12) | 2.10 (1.63–2.72) | |||||
| RISK ALLELE | ||||||||||
| GENOTYPIC MODEL | ||||||||||
| 5.8E-5 | 0.001 | 2.4E-9 | 1.63E-12 | 6.57E-9 | ||||||
| ODDS RATIO (95% CI) | 2.30 (1.53–3.46) | 1.52 (1.17–1.97) | 2.23 (1.71–2.90) | 2.44 (1.90–3.12) | 2.37 (1.77–3.18) | |||||
*Adjusted for Age, Gender, and BMI.
Putative Role of the associated variants with T2D in studied population (North-west India) utilizing the information from the various databases including GTEX, UCSC genome browser and HSF.
| Variant | Location of the variant w.r.t nearest gene | Allele Ref/Alt (Risk allele)* | eQTL gene | eQTL Tissue | eQTL sample size | eQTL NES | eQTL | eQTL m-value | Putative role (cis- eQTL) of variant | Regulatory role of variant (ENCODE and Haploreg data) | Splicing effect[ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| rs9419958 | 1st intron variant of | T/C (C) | Pancreas | 220 | 0.221 | 1.9E-3 | 1 | Significant and Up regulation | H3K27ac_Enh/H3K4me3_Pro / H3K4me1_Enh/ H3K9ac_Pro/7_Enh/4_PromD2/TSSA/9_Txresg | Creation of ESE intronic site/ SF2/ASF (IgM-BRCA1)-91.23 | |
| Adipose-subcutaneous | 385 | 0.226 | 1.1E-4 | 1 | Significant and Up regulation | H3K27ac_Enh/H3K4me3_Pro / H3K4me1_Enh/ H3K9ac_Pro/TSSAFlnk/3_PromD1 | |||||
| Skeletal Muscle | 491 | 0.0057 | 0.9 | 0 | Non-Significant | H3K27ac_Enh/H3K4me3_Pro / H3K4me1_Enh/ H3K9ac_Pro/TSSAFlnk/3_PromD1 | |||||
| rs4783704 | intergenic variant of | C/T (C) | N/A | Pancreas | N/A | N/A | N/A | N/A | N/A | 22_PromP | Creation of ESE intronic site/ Creation of new site for SRp55–86.86 and 9G8–60.67 |
| Adipose-subcutaneous | H3K27ac_Enh/ H3K4me1_Enh/14_EnhA2 | ||||||||||
| Skeletal Muscle | H3K27ac_Enh/ H3K9ac_Pro/16_EnhW1 | ||||||||||
| Transcription factors binding sites including | |||||||||||
| rs16847897 | upstream to | G/C (C) | Pancreas | 220 | −0.169 | 0.1 | 0.924 | Non-Significant | No Role w.r.t studied tissues | Creation of binding site for SF2/ASF (IgM-BRCA1)-75.85 and SRp55 site broken-100 | |
| Adipose-subcutaneous | 385 | −0.208 | 3.7E-5 | 1 | Significant and Down regulation | ||||||
| Skeletal Muscle | 491 | −0.139 | 0.03 | 0.965 | Significant and Down regulation | ||||||
| rs10936599 | upstream to | C/T (C) | Pancreas | 220 | −0.02 | 0.9 | 0.298 | Non-Significant | H3K27ac_Enh/H3K4me3_Pro/ H3K4me1_Enh/H3K9ac_Pro (Pancreas) H3K27ac_Enh/H3K4me3_Pro/ H3K4me1_Enh/H3K9ac_Pro (Adipose-subcutaneous) H3K27ac_Enh/H3K4me3_Pro/ H3K4me1_Enh/H3K9ac_Pro (Skeletal Muscle) | Creation of ESE intronic site/Creation of new site for SRp40–82.10 and SC35–82.42 | |
| Adipose-subcutaneous | 385 | −0.28 | 7.6E-8 | 1 | Significant and Down regulation | ||||||
| Skeletal Muscle | 491 | −0.123 | 0.07 | 0.841 | Non-Significant | ||||||
| Pancreas | 220 | 0.171 | 0.05 | 0.938 | Non-Significant | ||||||
| Adipose-subcutaneous | 385 | 0.099 | 0.03 | 0.97 | Significant and Up regulation | ||||||
| Skeletal Muscle | 491 | 0.106 | 2.2E-3 | 0.99 | Significant and Up regulation | ||||||
| rs74019828 | 4th intron variant of | G/A (G) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | No Role w.r.t studied tissues | Creation of new binding site for SC35–75.17 |
*Risk allele in this study; NES – Normalized Effect Size in eQTL; m-value – posterior probability that effect exists in each tissue, ranges between 0 and 1; H3K27Ac_Enh – chemical modification (acetylation) of the histone proteins (H3) at lysine 27 and associated with transcriptional initiation and open chromatin structure (active enhancer); H3K4me3 – chemical modification (methylation) of the histone proteins (H3) at lysine 4, marks promoters that are active or poised to be activated; H3K4me1 – chemical modification (methylation) of the histone proteins (H3) at lysine 4 and is associated with enhancers, and downstream of transcription starts.; H3K9ac – chemical modification (acetylation) of the histone proteins (H3) at lysine 9 and is associated with transcriptional initiation and open chromatin structure; Enh – Enhancers; Pro – Promoters; TSSA – active transcription start site; TxReg – transcription regulatory; PromD1 – promoter downstream TSS; TSSAFlk – Flanking TSS; 22PromP – poised promoter; EnhW1 – weak enhancer; EnhA2 – active enhancer 2; the H3K4me1/2/3 and H3K36me2/3 are linked with genomic region which actively transcribing and H3K9me3, H3K27me3 and H4K20me3 with non-transcribing region; ESE – Exonic Splicing Enhancers; SR – Serine-Arginine rich proteins; 9G8, SC35 – SR splicing factor; SF2/ASF (IgM-BRCA1) – Serine-Arginine rich proteins; #Supplementary Fig. S1.